← All trials
NCT06331299
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 29, 2024
- Primary completion
- Mar 31, 2025
- Completion date
- Mar 31, 2026
- First posted
- Mar 26, 2024
- Last posted
- Sep 19, 2024
- Enrollment
- 87
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- UroGen PharmaLead sponsor
- UroGen PharmaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.